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Medical Microbiology, School of Medicine, Cardiff University, Heath Park, Cardiff, United Kingdome
The uncontrolled, often inappropriate use of antibiotics has resulted in the increasing prevalence of antibiotic-resistant patho-
gens, with major cost implications for both United States and European health care systems.We describe the utilization of a low-
molecular-weight oligosaccharide nanomedicine (OligoG), based on the biopolymer alginate, which is able to perturb multi-
drug-resistant (MDR) bacteria by modulating biofilm formation and persistence and reducing resistance to antibiotic treatment,
as evident using conventional and robotic MIC screening andmicroscopic analyses of biofilm structure. OligoG increased (up to
512-fold) the efficacy of conventional antibiotics against important MDR pathogens, including Pseudomonas, Acinetobacter, and
Burkholderia spp., appearing to be effective with several classes of antibiotic (i.e., macrolides, -lactams, and tetracyclines). Us-
ing confocal laser scanning microscopy (CLSM) and scanning electronmicroscopy (SEM), increasing concentrations (2%, 6%,
and 10%) of alginate oligomer were shown to have a direct effect on the quality of the biofilms produced and on the health of the
cells within that biofilm. Biofilm growth was visibly weakened in the presence of 10%OligoG, as seen by decreased biomass and
increased intercellular spaces, with the bacterial cells themselves becoming distorted and uneven due to apparently damaged cell
membranes. This report demonstrates the feasibility of reducing the tolerance of wound biofilms to antibiotics with the use of
specific alginate preparations.
The evolution of multidrug resistance (MDR) represents an in-creasingly formidable challenge in the developed and develop-
ing worlds, having a colossal clinical and economic impact (26).
This escalating problem is a major world-health issue, com-
pounded by the lack of new antibiotics in development, particu-
larly for Gram-negative MDR bacteria. The need for new strate-
gies to improve the diagnosis and treatment of these infections is,
therefore, acute (15, 16).
In vivo, the inability to eradicate bacteria from a diverse num-
ber of clinical situations ranging from the periodontal pocket to
the cystic fibrosis (CF) lung has been attributed to the acquisition
of a biofilm state (12, 13). Antimicrobial resistance can also arise
by a plethora of mechanisms involving chromosomal mutations
or horizontal gene transfer. Resistance may result from destruc-
tion of the antibiotic by, e.g.,-lactamases, typified by the recently
described New-Delhi metallo--lactamase-1 (NDM-1) (21); mu-
tations in specific antibiotic target sites, e.g., RNA polymerase and
DNA gyrase (22); limitation of local antibiotic concentrations due
to outer membrane lipid bilayer modifications or porin-mediated
permeability (5); the action of specific multidrug efflux pump
mechanisms, e.g., MexAB-OrpM (28); acquisition of resistance
genes such asmecA in methicillin-resistant Staphylococcus aureus
(MRSA) (22); or the sequestration of antibiotics within the bacte-
rial biofilm (25).
Attempts to develop (and screen) alternative antibacterial
strategies to potentiate the activity of conventional antibiotics are
becoming increasingly important. Antibacterial strategies have in-
cluded use of antimicrobial cationic peptides (AMPs) (7); cell
membrane permeabilization (7); molecular chaperones (e.g., heat
shock proteins) (4); inhibitors of RecA-mediated strand exchange
(34); inhibitors of DNA synthesis (6); inhibitors of penicillin-
binding protein production (18); and use of efflux pump inhibi-
tors or inhibitors of beta-lactamase expression (27). Despite al-
most 20 years of intense research, none of these agents deemed
useful in vitro have progressed to clinical use.
Alginate is a biopolymer which is found in brown algae and
bacterial extracellular polysaccharide (EPS) and is a linear poly-
mer composed of (1–4)-linked-L-guluronate (G) and-D-man-
nuronate (M) residues. It is extensively utilized in foods andmed-
icines (e.g., wound dressings) due to its physical cross-linking and
gel-forming properties (30). Sodium alginate is recognized as safe
by the U.S. Food and Drug Administration (reference no.
21CFR184.1724). While naturally occurring alginate is polydis-
persed in relation to molecular weight and G/M composition, it is
possible to generate polymers of defined molecular weight and
also G/M composition (11), which have been employed to mod-
ulate immunological responses in vivo (35). Previous workers
have highlighted the potential of nanoscale biosensor-based diag-
nostics for the detection of life-threatening bacterial infections
(16). We describe here the development of the first polymer ther-
apeutics (based on alginate oligosaccharides) designed to specifi-
cally modulate bacterial responses and treat infections of MDR
bacteria, with phase IIa human clinical studies under way.
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MATERIALS AND METHODS
Bacterial strains. The strains used for susceptibility testing are shown in
Table 1. They include both culture collection strains and clinical isolates:
Pseudomonas aeruginosa (n 4), Burkholderia spp. (n 4),Acinetobacter
spp. (n 4), Enterobacteriaceae spp. (n 4), Staphylococcus aureus (n
3), and Streptococcus oralis (n  1). These isolates represent the most
frequently encountered resistance types (aminoglycosides, carbapenems,
cephalosporins, fluoroquinolones, monobactams, and penicillins).
Bacterial media and culture conditions. Bacterial colonies were
grown on blood agar base no. 2 (BA; LabM) supplemented with 5% horse
blood and tryptone soya broth (TSB; Oxoid) for liquid cultures. Biofilms
were generated in cation-adjusted Mueller-Hinton (MH) broth (LabM).
Biofilms were washed with phosphate-buffered saline (PBS). All antibiot-
ics (Sigma-Aldrich, Gillingham, United Kingdom, or Bristol-Myers
Squibb Pharmaceuticals Ltd.) used were pharmaceutical grade and in-
cluded themajor classes of antibiotics (-lactams, aminoglycosides, mac-
rolides, tetracyclines, carbapenems, and polymyxins) employed in the
treatment of these organisms. Ultrapurified pig gastric mucin glycopro-
tein (purified by Jeff Pearson, Newcastle University) and OligoG (2,600
Da, 90 to 95% G) were provided by AlgiPharma AS, Sandvika, Norway.
Synthesis of alginate oligosaccharides. OligoG was generated from
alginate extracted from the stem of the locally sourced brown seaweed
Laminaria hyperborea. Purification and fractionation of the resulting ma-
terial yielded an oligomer with a high content of guluronate and a rela-
tively narrow molecular-weight distribution. Final purification using
charcoal filters was followed by spray drying. The test OligoG had 90% to
95% of the monomer residues as G residues (mean, 2,600 Mw; Fig. 1A).
Purified OligoG was characterized by hydrogen-1 nuclear magnetic reso-
nance (H-NMR) (Fig. 1B) and high-performance anion-exchange chro-
matography with pulsed amperometric detection (HPAEC-PAD; Fig.
1C). OligoG is anionic and highly soluble, although its solubility is limited
by viscosity at higher concentrations (15%), the rise in viscosity being
offset to a degree by an increase in temperature. OligoG was tested at
working concentrations of 2% to 10%, phase 1 studies having demon-
strated that these concentrations are safe for clinical use (clinical phase
1 safety and toxicology studies; www.clinicaltrials.gov [identifier,
NCT00970346]).
Alginate oligosaccharides of similar molecular weights but altered M
content were generated via epimerisation technology and also tested. M-
rich alginates (puremannuronan) from a nonpathogenic high-expressing
mutant (P. fluorescens NCIMB10525) were used as a substrate for man-
nuronan C-5-epimerase AlgE4, converting alternating M residues on the
alginate backbone into G residues. These were developed with similar
molecular-weight profiles and defined, based on G:M composition, as
OligoM(100%M; 3,000 to 3,500Mw) (11) andOligoMG(46%G; 4,000 to
4,500Mw) (3).
Effects ofOligoGonbacterial growth in liquid culture.The effects of
alginate oligosaccharide OligoG on a collection of clinically relevant hu-
man Gram-negative and Gram-positive MDR and non-MDR pathogens
(Table 1) were studied using robotic high-throughput screening (HTS;
Beckman-Coulter) and conventional screening and a range (0% to 10%)
of OligoG concentrations. Overnight (O/N) bacterial cultures grown in
tryptone soya broth (TSB) were inoculated into Mueller-Hinton (MH)
broth with increasing concentrations (0%, 2%, 6%, and 10%) of OligoG
in microtiter plates. After cultivation for 19 h, cell densities were deter-
mined by measuring optical density at 600 nm (OD600). The OligoG-
induced reduction in optical density observed in these assays correlates
directly with reduced bacterial dry weight/biomass (data not shown).
Growth of biofilms for SEM imaging or LIVE/DEAD staining. The
ability of OligoG to modulate the development of biofilms as well as their
effect on 24-h biofilms in vitro was investigated. Overnight cultures of P.
aeruginosa PAO1 were grown in TSB. After dilution of the bacterial cul-
tures to 0.5 McFarland in MH broth with mucin (2.5 g/liter), 1 ml was
transferred to the wells of a flat-bottom 12-well plate containing sterile
plastic Thermanox coverslips (Agar Scientific, Essex, United Kingdom)
for scanning electronmicroscopy (SEM) or glass coverslips (Fisher Scien-
tific) for confocal laser scanning microscopy (CLSM). Plates were then
wrapped in parafilm to prevent dehydration and incubated at 37°C for 6 h
to allow biofilm formation. Planktonic cells and supernatant were re-
moved and biofilms washed with 1 ml sterile PBS. Cells then were treated
with a combination of OligoG (0%, 2%, 6%, and 10%) and mucin (2.5
g/liter) in 1 ml MH broth. Plates were then wrapped in parafilm and
incubated at 37°C for 24 h with gentle agitation.
TABLE 1 Strains used for susceptibility testing and their known relevant genotypesa
Strain no. Strain designation Relevant genotype(s) Origin
V1 Pseudomonas aeruginosa (R22) VIM-2, aac61b, aadA7b,c China
V2 Pseudomonas aeruginosa (301) VIM-2b,c Poland
V13 Pseudomonas aeruginosa (PAO1, ATCC 15692) Australia
V79 Pseudomonas aeruginosa (ATCC 39324) United States
V33 Burkholderia cepacia (ATCC 25416) —c United States
V51 Burkholderia contaminans (LMG 23255) —c Czech Republic
V52 Burkholderia cenocepacia (AU1054) —c United States
Burkholderia dolosa (LMG 18941) United States
V19 Acinetobacter baumannii —b,c United Kingdom
V9 Acinetobacter baumannii VIM-2b,c Egypt
V4 Acinetobacter baumannii —b,c Libya
V22 Acinetobacter lwoffii NDM-1b,c United Kingdom
V10 Acinetobacter lwoffii VIM-2b,c Tunisia
V3 Klebsiella pneumoniae NDM-1b,c India
V6 Klebsiella pneumoniae NDM-1b,c India
V5 Escherichia coli AIM-1b,c Australia
V7 Escherichia coli NDM-1b,c India
U204 Staphylococcus aureus NCIMB 9518 United States
E68 Staphylococcus aureus NCTC 6571 United Kingdom
U50 Staphylococcus aureus 1040 (MRSA) mecA United Kingdom
V17 Streptococcus oralis 5610 United Kingdom
a AIM-1, metallo--lactamase; NDM-1, New Delhi metallo--lactamase; MRSA, methicillin-resistant Staphylococcus aureus.
b Sensitive to colistin only.
c MDR, multidrug resistant (resistant to 3 or more classes of antibiotic).
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SEM of OligoG-treated Pseudomonas biofilms. Glutaraldehyde was
added to OligoG-treated biofilms at a final concentration of 1.25% and
fixed at room temperature for 24 h. The samples were dehydrated in a
graded series of ethanol concentrations, dried in a critical point dryer
(CPD 030; Balzers, Germany), mounted on aluminum stubs, coated with
gold in a sputter-coater (model AE 1231; EMscope, United Kingdom),
and then viewed on a scanning electron microscope (XL-20; FEI-Philips,
The Netherlands).
LIVE/DEAD staining andCLSMofOligoG-treated biofilms.The ef-
fect of OligoG on cell membrane integrity (a measure of cell death) was
investigated using LIVE/DEAD BacLight stain (bacterial viability kit; In-
vitrogen). A 2-l volume of each stain (green fluorescent SYTO9 and
red-fluorescent propidium iodide) was added to 1 ml NaCl (0.85% [wt/
vol]) and mixed and 100 l added to each test sample. The preparation
was incubated in the dark for 15 min and then analyzed by CLSM using a
Leica TCS SP2 AOBS spectral confocal microscope (Leica, Wetzlar, Ger-
many).
OligoG-treated gfp-labeled Pseudomonas aeruginosa PAO1 bio-
films and staining of biofilmmatrix for CLSM. A gfp (green fluorescent
protein)-labeled P. aeruginosa PAO1 derivative (20) was also used for
CLSM.Overnight cultures of gfp-PAO1were grown inTSB, and 10l was
used to inoculate 1mlMHbrothwith orwithout 2%, 6%, or 10%OligoG.
Then, 200 l of each was transferred to individual Coverwell incubation
chamber gaskets (Invitrogen) with the addition of 40 l BODIPY 630/
650-X SE stain (Invitrogen), which stains extracellular polysaccharide
(EPS) matrix components. The chamber gaskets were then sealed with a
Histobond (R. A. Lamb Ltd., Eastbourne, United Kingdom) positively
charged slide. Each unit was inverted and incubated for 18 h at 37°C to
allow biofilm formation on the Histobond slide. Coverwell incubation
chamber gaskets and any supernatant and planktonic cells were removed
from theHistobond slide and replacedwith a glass coverslip. Undisturbed
biofilms were then visualized by CLSM as described above.
Susceptibility testing byMIC assay. Potentiation of alginate oligom-
ers was studied using standard MICs (19) and confirmed by robotic HTS
using a range of international MDR (i.e., resistant to 3 or more classes of
antibiotics) and non-MDR Gram-negative and Gram-positive clinical
isolates (Table 1). Isolates were grown overnight in TSB and then diluted
in PBS until the OD625 was between 0.08 and 0.10 (equivalent to 0.5
McFarland standard; approximately 108 CFU/ml). Two-fold antibiotic
serial dilutions were prepared in MH broth or MH broth with OligoG at
2%, 6%, or 10% in flat-bottom 96-well microtiter plates (100 l in each
well). The diluted bacterial cultures were diluted 10-fold in MH broth,
and 5l was added to themicrotiter plates containing the antibiotic serial
dilutions to give a final concentration of 5  105 CFU/ml. Plates were
incubated at 37°C for 16 to 20 h and MICs determined as the lowest
concentration at which there was no visible growth. As well as conven-
tional culture, a robotic high-throughput screening system (see below)
was used to determine MICs.
Robotic HTS. Serial dilutions for MIC determinations were per-
formed with a Tecan Genesis RSP 200 liquid-handling workstation
equipped with an 8-channel pipetting tool using sterile disposable 200-l
barrier tips. The optical density of the cultures was measured using a
Beckman Coulter Robotic Core system with an integrated Beckman
Coulter Biomek NXP robotic liquid-handling unit, a Thermo Cytomat 2
450 S robotic incubator, and a Beckman Coulter Paradigm microplate
reader. The 384-well microplates were incubated at 37°C for 19 h. The
microplates were shaken at 1,800 rpm (2.5-mmamplitude) for 120 s prior
to taking absorbance readings at 600 nm. HTS was used for determining
FIG 1 Structure, purification, and quality control of OligoG. (A) Structures of -L-guluronate (G) and -D-manuronate (M); OligoG has at least 90% to 95%
of themonomer residues asG residues. (B)NMR spectrumofOligoG containing 96%G. (C)Characterization ofOligoGwith high-performance anion-exchange
chromatography with pulsed amperometric detection (HPAEC-PAD).
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the growth curves obtained at various concentrations of OligoG as well as
for confirming the results from the conventional MIC testing.
Effectofpulmonary surfactantonantimicrobial efficacyofOligoGs.
Previous studies have shown that surfactants in the lung can interact with
antibiotics, for example, with daptomycin (33), resulting in an inhibition
of antibacterial activity. Here, beractant (Survanta) (a natural bovine lung
extract) was used to mimic lung surfactant to determine whether it inter-
fered with the ability of the OligoG to enhance antibiotic antimicrobial
activity. In these experiments, 10% beractant was incorporated into the
MIC test with OligoG.
When beractant was added to MH broth, a white precipitate formed
and persisted, even after incubation of theMIC plate at 37°C overnight. It
was unclear if this apparent cloudiness was due to the beractant precipi-
tating or to bacterial growth. As this obscured reading of the plates, to
determine the MIC values for beractant, it was necessary to subculture 5
l from each well of the MIC plate into fresh MH broth with overnight
incubation at 37°C prior to determining the correct cutoff points between
regrowth and clear wells.
Effect ofOligoGonMexAB-OrpMeffluxpumpmutants.MICassays
were carried out as described above with or without OligoG using efflux
pump P. aeruginosa PAO1 mutant strains alongside the wild-type strain.
These included strain K1169, a mexB knockout lacking MexAB-OprM,
and a nalB hyperexpression mutant of MexAB-OprM (10).
Effect of OligoG on bacterial motility. Twomethods of motility test-
ing were used. For the plate assay, overnight (O/N) cultures of Proteus
mirabilis (NSM6) and Pseudomonas aeruginosa (PAO1) were grown in
TSB at 37°C. Cultures were diluted 1:100 inMHbroth supplementedwith
0%, 0.2%, 0.5%, 2%, 6%, or 10%OligoG and reincubated for 18 h at 37°C.
Iso-sensitest (ISO) agar plates (Oxoid) containing 0%, 0.5%, 2%, or 6%
OligoGwere prepared and inoculatedwith 10l of theMHcultures. (ISO
plates with 10%OligoG were not used, as they did not set at that concen-
tration.) Plates were incubated for 23 h at 37°C and values for distance of
bacterial spread recorded at 2, 5, 7, 13, and 23 h.
For the stab assay, overnight cultures of P. mirabilis (NSM6) and P.
aeruginosa PAO1 and control isolates of P. mirabilis (NCTC 11938),
Staphylococcus aureus (NCTC 6571), P. aeruginosa (NCTC 10662), and
Escherichia coli (NCTC 10418) were prepared in MH broth with or with-
out OligoG as described above. Motility Test Agar (MTA; Mast Group
Ltd., Bootle, United Kingdom) was supplemented with 0%, 0.2%, 0.5%,
2%, and 6% OligoG, with 5 ml pipetted into sterile bijou tubes. (MTA
containing 10% OligoG also did not set.) The MTA was stab inoculated
with the prepared MH broth cultures and incubated for 24 h at 37°C.
Motility appeared as a progressive lateral diffuse pink/red color in the
MTA and was scored from 0 to 4 as previously described (2). Absence of
growth beyond the track of inoculation was scored as 0, and growth
throughout the medium was scored as 4.
Testing development of resistance to OligoG. Daily subculturing of
P. aeruginosa PAO1 in MH broth or MH broth with 10% OligoG was
carried out over a 16-day period (160 generations). Serial passage in
escalating concentrations (0.1%, 1%, and 10%) of OligoG was also un-
dertaken (n 7 days for each concentration). MIC assays of the control
and test cultures (on day 16 and day 21, respectively) were then performed
to see if there were any apparent differences.
RESULTS
Effects ofOligoGon growth ofMDRbacteria.OligoGwas found
to reduce bacterial proliferation in liquid culture at 19 h (Fig. 2).
This effect was dose dependent for the concentration range inves-
tigated (0%, 2%, 6%, and 10%), showing a general decrease in
percent change (compared to the control) with increasing OligoG
concentration. These effects were particularly striking for the
Gram-negative pathogens P. aeruginosa, A. baumannii and Burk-
holderia spp., and Enterobactericeae.
Effects of OligoG on biofilms generated byMDRGram-neg-
ativebacteria examinedusing conventional light, scanning elec-
tron, and confocal laser scanning microscopy. SEM, LIVE/
DEAD BacLight staining of PAO1 biofilms, and CLSM of gfp-
labeled PAO1 biofilms generated in the presence of OligoG
revealed dose-related changes (Fig. 3). Increasing concentrations
(0% to 10%) of OligoG resulted in disruption of established 24-h
biofilms (demonstrable by cell damage and disruption of cellular
content as visualized by SEM), increased cell death (LIVE/DEAD
staining), and decreased cellular density (CLSM) in the developed
biofilm. CLSM showed that OligoG was able to considerably re-
duce gfp-labeled PAO1 biofilm formation, with clear dose-depen-
dent alterations in the 3-dimensional structural organization of
cells in the biofilm. These changes were also associated with in-
FIG 2 Effect of increasing concentrations of OligoG (0%, 2%, 6%, and 10%) on cell densities after cultivation for 19 h for various Gram-negative bacterial
species. (*, data not significantly different from control results; P 0.05).
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creasing numbers of nonviable bacteria seen by LIVE/DEAD
staining.
The ability of alginate oligomers to potentiate the effect of
existing antibiotics on Gram-negative MDR pathogens. The
ability of alginate oligomers to potentiate the activity of the prin-
cipal classes of antibiotics commonly employed in clinical practice
in the treatment of Gram-negative infections (cephalosporins,
macrolides, quinolones,monobactams, tetracyclines, and carbap-
enems) was assessed, with selected results for three antibiotic
classes shown in Table 2.
OligoG treatment reduced (by up to 512-fold) the MICs of a
range of antibiotics, including macrolides (azithromycin, eryth-
romycin, spiromycin, and clarithromycin), aztreonam, ceftazi-
dime, oxytetracycline, and ciprofloxacin. For example, P. aerugi-
nosa V2 showed a ceftazidime MIC reduction from 16 to 0.5 g/
ml, representing a change from untreatable (8 g/ml) (9) to
treatable (8 g/ml) levels (0% and 10% OligoG, respectively;
Table 2). This potentiation effect was particularly marked for the
genus Burkholderia. Interestingly, while this potentiation was not
seen in the control OligoMG oligomer, a similar, although
smaller, effect (up to 32-fold reduction for P. aeruginosa and A.
baumannii; data not shown) was evident in part for OligoM. Spe-
cific antibiotic combination effects (using two antibiotics) were
also particularly evident (data not shown); for example, using A.
baumannii and ceftazidime or ciprofloxacin with azithromycin at
1 g/ml and 10% OligoG resulted in a reduction in the MIC of
these combination antibiotics to 1 g/ml or 0.25 g/ml, re-
spectively (representing a512-fold reduction). Similar potenti-
ation, although a lesser effect, was observed with Gram-positive
isolates (Table 2). OligoG-antibiotic synergy was not evident for
every combination studied. Moreover, no potentiation was seen
for the aminoglycoside (tobramycin and amikacin) or the poly-
myxin (colistin) antibiotics for any bacteria tested.
Antimicrobial susceptibility testing, performed in the presence
and absence of artificial surfactant (to mimic the lung environ-
ment and investigate any potential nonspecific inhibition which
may occur in vivo), showed no apparent effect of OligoG at any
tested concentration (0% to 10%; data not shown).
Mechanistic cellular andmolecular studies to determine the
mode of action of OligoG. The addition of OligoG appeared to
modulate cellular structure. However, this did not appear to cor-
relate with increased bacterial cell membrane permeability, as the
effect contrasted with that observed with an EDTA control (data
not shown). Longitudinal studies employing P. aeruginosa PAO1
MexAB-OrpM mutants also demonstrated that the effect of
OligoG was not mediated via interaction with this efflux pump
system, as no differences in MIC determinations with OligoG
were noted using wild-type strains or knockout or hyperexpres-
sion mutants of MexAB-OrpM, showing that OligoG was not a
substrate of MexAB-OrpM (data not shown). Interestingly, mo-
tility test agar stabs showed that OligoG (6%) was able to almost
completely inhibit motility in P. aeruginosa, E. coli, and P. mirabi-
lis (Fig. 4A). Furthermore, swarming motility in Proteus sp. was
inhibited in a dose-dependentmanner with increasing concentra-
tions of OligoG (0% to 6%), but the effect was predominant in the
presence of OligoG (Fig. 4B). Importantly, when the bacteria were
exposed to OligoG only in the initial liquid growth medium (and
not in the agar plate onto which they were then inoculated), the
FIG 3 Growth of 24-h Pseudomonas aeruginosa PAO1 biofilms in 0%, 2%, 6%, or 10% OligoG visualized by scanning electron microscopy (SEM) or confocal
laser scanning microscopy (CSLM) of LIVE/DEAD staining (green, live; red, dead) or CSLM of green fluorescent protein (Gfp)-labeled PAO1 with counter-
staining using BODIPY 630/650-X SE extracellular polysaccharide dye.
Khan et al.
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effect of OligoG was almost, but not quite, completely lost, show-
ing a slight “carryover” of effect after exposure to OligoG was
removed (Fig. 4C).
Resistance to OligoG. MIC determinations of P. aeruginosa
PAO1 grown in OligoG for prolonged serial subculture and in
escalating concentrations of OligoG showed that there was no
difference between the test (with OligoG) and control results, in-
dicating no buildup of resistance to OligoG in this time period
(data not shown).
DISCUSSION
The functional properties of alginates are strongly correlated with
their M/G ratio and with their uronic acid sequence (31). Initial
experiments showed that treatment with OligoG impaired bacte-
rial growth. These observed effects were bacteriostatic andmay be
related to the ability of alginates to chelate cations, particularly
iron (32). G subunits are known to show preferential binding to
cations such as Ca2, although not all cations appear to utilize the
G subunits as preferred binding sites (24). The magnitude of the
antimicrobial effect was considerably potentiated using these low-
molecular-weight OligoG oligomers. This inhibition was evident
in the studies on bacterial biofilms, where OligoG not only inhib-
ited biofilm formation and resulted in disruption of established
24-h biofilms but also potentiated antibiotic treatment. This ob-
servation was at first counterintuitive, as alginate per se is an im-
portant component of the EPS of certain bacterial biofilms and
therapies targeting alginate, e.g., alginate lyases are currently being
developed as antibiofilm therapies (23).However, unlike alginates
derived from algae, bacterial alginates frommost bacteria, such as
P. aeruginosa, differ considerably structurally, having an absence
of G blocks (homopolymeric regions of poly-L-guluronate) (31),
which may be a contributing factor in these observed antimicro-
bial effects.
Structural analysis of the biofilms indicated that OligoG treat-
ment was associated with increased cellular “clumping” and dis-
ruption of cellular contents. Hence, the mechanism by which
OligoG exerts its effect could simply have been the result of per-
meabilization of the bacterial membrane, which is the mode of
action of a number of antibiotics.However, permeabilization does
not appear to be responsible for the cellular membrane changes
induced by OligoG treatment, since they contrasted markedly
with those observed with permeabilizing agents (EDTA; data not
shown). This membrane effect, independent of permeability
changes, was reassuring, as, while a number of “permeabilizing”
antimicrobial agents have been developed, progress to clinical
utility has been hampered by formulation difficulties and nonspe-
cific permeabilization-toxicity concerns (14). The lack of permea-
bilization reflected the bacteriostatic activity of the oligomers ob-
served in the HTS growth assay. OligoG treatment (both alone
and in combination with antibiotics) clearly altered the bacterial
membrane. Membrane disruption in AMPs, via the ionic dis-
placement of divalent cations (Mg2 and Ca2), has been previ-
ously described and is a recognized mechanism by which the ac-
tion of antibiotics may be potentiated (8). While many
antimicrobials act on the biosynthetic pathways of growing cells,
the bacterial membrane represents an important target in the
treatment of quiescent nonreplicating bacteria in recalcitrant in-
fection such as the CF lung (17). A number of agents have been
developed that modulate changes in the bacterial membrane (via
alterations in NADH2 and ATP synthase and, indirectly, via gen-
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eration of lethal reactive oxygen species and nitric oxide in the
bacterial membrane). The observation of the putative, but as-yet-
unidentified, membrane effect seen with OligoG is supported by
the observed failure to develop resistance during prolonged treat-
ment in longitudinal experiments. Weakened swarming motility
has been shown to lead to an impaired ability to form simple
biofilms (29). The impairment of bacterial motility by OligoG
may, at least in part, explain its mode of action in motile bacteria.
The finding thatOligoG exhibits activity against a number of non-
motile bacterial species indicates, however, that other mecha-
nisms are undoubtedly involved.
The potentiation of antibiotic therapy in the treatment of
MDR organisms in persistent infections is a major goal of anti-
infective therapy (17). Indeed, synergistic combined therapies ap-
pear to have increasing potential for future antibacterial therapies
(1). In characterizing the ability of OligoG to potentiate the activ-
ity of conventional antibiotics against MDR organisms, we uti-
lized conventional microbiological MIC assays. These experi-
ments demonstrated that exposure to OligoGwas able to decrease
the MIC values of Gram-negative pathogens up to 512-fold in a
range of MDR organisms tested. Moreover, the MIC levels were
significantly reduced for a number of important Gram-negative
and, to a lesser extent, Gram-positive pathogens (including
MRSA). Furthermore, OligoG proved effective against a variety of
multi- and pan-drug-resistant pathogens for which there are cur-
rently no or only limited treatments available and hence are often
associated with mortality in infected individuals or which repre-
sent potential agents of bioterrorism (e.g., Burkholderia spp.).
EUCAST MIC breakpoint tables (11) describe the use of azithro-
mycin for the treatment of Salmonella enterica serovar Typhi in-
fections with an MIC of 16 mg/liter (for wild-type isolates). In
this study, other Enterobacteriacae (encoding NDM-1) such as
Escherichia coli (V7) showed an 8-fold MIC decrease for azithro-
mycin, indicative that potentiation with OligoG had moved
theMIC from16g/ml in the resistance category (i.e., above the
breakpoint) to16g/ml in the sensitive category (i.e., below the
breakpoint). Synergistic activity for organisms such as Burkhold-
eria spp. is encouraging, since Burkholderia infection is associated
with a fatality rate of almost 50% in infected cystic fibrosis pa-
tients. Overall, OligoG provides a major advancement in thera-
peutic development for the treatment ofGram-negative infections
such as those caused by Burkholderia and Acinetobacter spp. for
which effective treatment is currently extremely limited.
OligoG has been screened and proven for safety and tolerabil-
ity in a series of animal and human experiments. Due to their
physicochemical properties, alginates are widely employed in the
food and pharmaceutical industry, and the lack of toxicity of in-
haled (nebulized) OligoG in the animal and human phase 1 stud-
ieswas, therefore, unsurprising (data not shown).While a number
of in vitro antibiotic-potentiating agents have been cited in the
literature, in vivo many have problems with potential safety and
toxicity issues. The advantage ofOligoG is that it is effectively inert
and resists enzymatic degradation. The toxicity and pK studies
FIG 4 Motility testing. (A) Motility test agar with or without OligoG inoculated with S. aureus (negative control; NCTC 6571), P. aeruginosa (PAO1), E. coli
(NCTC 10418), or P. mirabilis (NSM6). (B) Broth cultures of P. mirabilis (NSM6) grown inMHbroth (noOligoG) and plated on ISO agar containing 0%, 0.5%,
2%, or 6%OligoG. (C) Broth cultures of P. mirabilis (NSM6) grown inMH broth with 0%, 0.5%, 2%, 6%, or 10%OligoG and plated on ISO agar (no OligoG).
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demonstrate that the putative doses at whichOligoG is effective in
vitro are safely attainable in the lung in vivo.
OligoG represents a novel target nanomedicine for future clin-
ical use. Its suitability for formulation in isotonic solution and
safety-pharmacokinetic profiles all favor human use. Further-
more, phase IIa human clinical studies in CF patients are now
ongoing.
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